Hot Stocks

Hot stocks are not about hype. They emerge when powerful themes, policy shifts, and capital flows converge. InvestorPlace analysts track fast-moving market narratives, especially in technology, AI, and infrastructure, to identify stocks drawing outsized attention and explain what is really driving those moves.

Novavax Stock Has a Clear Path to Over $200

By Mark R. Hake, CFA
Novavax is likely to recover with its vaccine results. If successful, I think its vaccine will make NVAX stock worth at least $229.

The Bullish Case for Aurora Cannabis Is so Close Yet so Far Away

By Chris Markoch, InvestorPlace Contributor
The long-term outlook for the cannabis market gives ACB stock an appealing bullish case, but that does nothing for investors in the near term.

9 Robinhood Stocks Flying Under the Radar

By Josh Enomoto, InvestorPlace Contributor
Robinhood stocks have generated much attention this year, but here are some names that you may not have heard about.

Pandemic Worries May Still Haunt Carnival Stock

By InvestorPlace Research Staff
On one hand, Carnival stock has been moving higher thanks to the resumption of international operations. But distinct concerns about the U.S. market make CCL one to wait on for a better discount.

Charlotte’s Web Earnings: CWBHF Stock Falls 5% on Q2 Misses

By Nick Clarkson, Web Editor
Charlotte's Web earnings on Monday have CWBHF stock falling a bit after the company missed both EPS and revenue estimates for the quarter.

Buy Luckin Coffee Shares and You’ll Only Get Burned

By David Moadel, InvestorPlace Contributor
There was a spike in the Luckin stock price, sure, but that doesn't mean investors should stay the course with this troubled company.

Nio Is Worth the Hype, But Wait for a Pullback

By Faizan Farooque, InvestorPlace Contributor
A steller quarter and favorable tailwinds is pushing Nio stock higher, but investors should wait for shares to cool off before loading up.

Let Fading Nikola Stock Go For Now

By InvestorPlace Research Staff
Nikola stock benefited from early hype before reversing. Given the valuation and risks, that reversal should continue; patience is advised.

Investors Should Cool Their Jets on JetBlue

By Muslim Farooque, InvestorPlace Contributor
JBLU stock is a risky bet with demand in the doldrums and the liquidity problems it may encounter after the expiration of the CARES Act

Upgrades Signal a Potential Blastoff for Virgin Galactic Stock

By David Moadel, InvestorPlace Contributor
Getting a nod from a financial analyst is encouraging. With multiple analysts recommending SPCE stock, the bull case is even stronger.

Nvidia Stock Rallies Monday on Arm Holdings Acquisition

By Sarah Smith, Editor-in-Chief, InvestorPlace.com
Nvidia stock is rallying Monday morning on news it secured a deal with SoftBank to buy Arm Holdings for $40 billion. Here's what it means.

Luckin Coffee Broke a Sacred Trust with Investors

By InvestorPlace Staff
As a speculation play, Luckin stock appeals thanks to broader fundamentals that support coffee culture in China. But the overriding reality is that investors don’t easily forget accounting scandals.

Pfizer Stock Pops on Vaccine Timeline News, Trial Expansion

By Sarah Smith, Editor-in-Chief, InvestorPlace.com
Pfizer stock and partner BioNTech are rallying Monday morning on news the two companies could vaccinate Americans before the end of 2020.

Plug Power Is in the Driver’s Seat as Hydrogen Use Grows

By Chris Lau, InvestorPlace Contributor
Mega deals for Plug Power from companies like Walmart and Home Depot are set to lift PLUG stock further.

The Reward of Buying Carnival Shares Isn’t Worth the Risk

By Chris Markoch, InvestorPlace Contributor
Carnival is taking its first steps toward normalcy, and CCL stock may have calmer waters ahead. Still, remaining risks may curtail growth.

CureVac Stock Is Just Another Part of a Bigger Story

By Chris Markoch, InvestorPlace Contributor
With its Covid-19 vaccine candidate, CureVac stock soared after its IPO in August. But as Operation Warp Speed wraps up, investors may wonder if there's anything else.

Sorrento Therapeutics Is a Scary, Risky Potential Buy

By Will Ashworth, InvestorPlace Contributor
Sorrento Therapeutics has lost 44% since firing its chief financial officer on Aug. 19. Is SRNE stock a buy given its drop in recent days?

Don’t Bother With United Airlines When Low-Cost Carriers Are Better Buys

By Thomas Niel, InvestorPlace Contributor
With a vaccine still in progress, and low-cost airlines better recovery plays, there's little reason to dive into UAL stock right now.

It’s Not Over Yet for Novavax Stock, but Wait for Another Pullback

By Thomas Niel, InvestorPlace Contributor
While factors could change the game, you can't say it's over for NVAX stock. Still, wait for lower prices before diving into high-risk, high-return Novavax.
Load More Articles